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Background: Despite consistent evidence linking smoking cessation pharmacotherapy 
  adherence to better outcomes, knowledge about objective adherence measures is lacking and little 
attention is given to monitoring pharmacotherapy use in smoking cessation clinical trials.
Objectives: To examine unannounced telephone pill counts as a method for assessing adher-
ence to smoking cessation pharmacotherapy.
Research design: Secondary data analysis of a randomized pilot study.
Participants: 46 moderate-to-heavy (.10 cigarettes per day) African-American smokers.
Main measures: Smokers received 1 month of varenicline (Pfizer Global Pharmaceuticals, 
New York, NY) in a pill box at baseline. Unannounced pill counts were completed by telephone 
4 days prior to an in-person pill count conducted at Month 1. At both counts, each compartment 
of the pill box was opened and the number of remaining pills was recorded.
Results: Participants were a mean age of 48 years (SD = 13), predominately female (59%), 
low income (60% , $1800 monthly family income), and smoked an average of 17 (SD = 7) 
cigarettes per day. A high degree of concordance was observed between the number of pills 
counted by phone and in-person (rs = 0.94, P , 0.001). Participants with discordant counts 
(n = 7) had lower varenicline adherence (mean [SD] = 77% [18%] vs 95% [9%], P , 0.0005), 
but reported better medication adherence in the past (1.0 [0.8] vs 2.8 [1.0], P , 0.0004) than 
participants with matching phone and in-person counts (n = 39).
Conclusion: Unannounced telephone pill counts appear to be a reliable and practical method 
for measuring adherence to smoking cessation pharmacotherapy.
Keywords: medication adherence, African-Americans, smoking cessation
Introduction
Tobacco use is the most preventable cause of disease and death, accounting for 443,600 
total deaths and more than 30% of all cancer deaths annually in the US.1 Nicotine replace-
ment therapies (NRTs) such as gum, patch, nasal spray, inhaler or lozenge, and two 
non-nicotine medications (bupropion (GlaxoSmithKline, Brentford, Middlesex, UK), 
varenicline (Pfizer Global Pharmaceuticals, New York, NY) are approved for the treat-
ment of tobacco dependence.2 While these pharmacotherapies have been shown to 
double or triple quit rates compared to placebo, adherence to the prescribed dose and 
treatment length is necessary to achieve the maximum drug effect.2–6
Despite the importance of patient adherence to smoking cessation medications, 
information on adherence to smoking cessation treatments is sparse. The limited evi-
dence that is available has consistently found that better adherence to pharmacotherapy 
is associated with higher rates of smoking abstinence.3–9 A study by Mooney et al 
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reported significantly higher week 3 and 6 abstinence 
rates among smokers with higher levels of adherence to 
bupropion,5 while another recently completed study found a 
two-fold increase in month 6 abstinence rates among partici-
pants taking varenicline on 80% of days or more compared 
to participants who did not meet this adherence threshold 
(52% vs 25%).7 As well, Shiffman et al found that the odds 
of abstinence at 6 weeks was three times greater among par-
ticipants adherent to nicotine patch compared to those who 
were non-adherent (53.2% vs 21.5%, respectively).6
Lack of attention to pharmacotherapy adherence in smok-
ing cessation studies may be due, in part, to lack of consensus 
on the best objective adherence measures.10 Methods of 
assessing adherence are divided into two categories: direct 
and indirect assessment. Direct assessment includes detection 
of the drug in biologic fluids, direct observation, and detec-
tion of biological markers. The common advantage of direct 
methods assessment is greater certainty that the drug has 
been consumed because there is no reliance on the truthful-
ness of the patient.2 Direct methods are not utilized as often 
as indirect methods because of cost feasibility. Detection of 
metabolites or drugs in biologic fluids such as blood or urine 
is a quantitative measure. This method of measurement is 
very accurate as it can confirm recent use of medication by 
detecting the levels in bodily fluids.11 Disadvantages include 
a limited time frame to use this measure, kinetic variations 
among individuals, high cost, and inconvenience to the 
patient.12,13 Direct observation assessment includes visually 
observing the patient consuming the medication. Advantages 
of this type of assessment include visual confirmation of 
medication consumption. However, direct observation is 
impractical for daily use and patients can hide pills in their 
mouths and later throw them away.12,13
Indirect methods of assessment, such as questionnaires, 
diaries, clinical response, prescription refills, electronic medi-
cation monitors, and pill counts, rely upon self-assessment 
by the patient, but the uncertainty about whether a patient 
has, in fact, consumed the medication is a disadvantage of 
indirect assessment.11–13 Questionnaires and diaries are the 
most basic level of self-reporting. They are advantageous 
because they help with recall, are effective in a clinical set-
ting, and are efficient in understanding a patient’s medica-
tion regimen. These methods are subject to recall bias and 
misinterpretation of questions may lead to over estimation of 
patient adherence.12 In general the rate of medication refill is 
an accurate method to evaluate medication adherence.13 The 
rates of prescription refills are a rapid and easy way to measure 
medication   adherence. In a Health Maintenance Organization 
or Universal Health Care system this is an effective way 
for physicians and health care providers to gain a scope of 
  adherence. The major disadvantage to this methodology is 
that obtaining the medication is not equivalent to consum-
ing or utilizing the medication.13 Electronic monitoring of 
  medication adherence is achieved through the use of the 
Medication Event Monitoring System (MEMS). MEMS has 
the ability to record and stamp the time of opening medication 
bottles, dispensing drops, or activation of canister.13 This type 
of device provides accuracy and precision on the exact timing 
of medication and regimens.12,13 While MEMS is a valid and 
reliable measure, there are many disadvantages to this method 
of analysis.11–13 First, the removal of the medication cap does 
not confirm that the patient actually took the medication. In 
addition, the poor health of smokers indicates that many of 
these individuals take a variety of medications for smoking 
attributable conditions. Therefore many smokers do not use 
individual medication bottles due to the number of medica-
tions they are prescribed; it is easier to use pill boxes for 
organization.12 These logistics suggest a major barrier in the 
use of MEMS for smokers and tobacco cessation medication 
adherence. In addition, MEMS technology is fairly expensive 
and unfeasible outside of clinical trials.14 Due to disadvan-
tages and inconsistencies in other measures, the pill count is 
a commonly used indirect adherence measure.15
Pill counts are an established, objective method for 
assessing medication adherence.13,16 However, they are lim-
ited by a number of factors. Notably, pill counts are typically 
conducted in-person and can be a burden to participants by 
requiring them to come to a clinic and remember to bring 
their medications.13,17 In-person pill counts may also be 
inaccurate if participants remove medications from their 
container in anticipation of a pill count. Unannounced pill 
counts completed by telephone may be a viable and more 
practical alternative. Unannounced telephone pill counts have 
been examined as an alternative to in-person pill counts in 
other health domains,16,18–20 but to our knowledge, have not 
been examined as a tool for assessing adherence to smoking 
cessation pharmacotherapy. Given the potential for pharma-
cotherapy adherence to improve tobacco treatment outcomes 
but the lack of objective, practical assessment tools, this study 
examined unannounced telephone pill counts for assess-
ing adherence to smoking cessation pharmacotherapy by 
comparing telephone counts to in-person counts completed 
approximately 4 days later. Demographic, psychosocial, 
and medication/treatment-related differences were also 
  examined between participants who had perfectly concordant 
vs   discrepant telephone and in-person pill counts.
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Methods
Parent study
The parent pilot trial, described in detail elsewhere, examined 
a behavioral intervention to encourage medication compli-
ance among African-American smokers taking varenicline.9 
  Participants were recruited through clinic-based efforts, 
including lobby recruitment and the use of posters and flyers, 
as well as through a tracking database of participants ineligible 
for another study who had given their consent to be contacted 
for future studies. Of the 308 people screened, 192 were medi-
cally ineligible, 116 were eligible and invited to participate, 
and 44 did not keep their baseline appointment, leaving a final 
sample of 72 participants. Medically eligible smokers were 
randomly assigned to Adherence Support (AS; n = 36) or Stan-
dard Care (SC; n = 36).   Participants   randomized to Standard 
Care received 3 months of   varenicline, standard quit   smoking 
educational materials, and counseling focused on setting a 
quit date. Participants randomized to Adherence Support 
received everything that Standard Care participants received 
plus five additional   counseling sessions to encourage adher-
ence to varenicline. Counseling sessions were conducted 
in-person on Day 0/Baseline (AS and SC), Day 12 (AS), 
Month 1 (AS), and Month 2 (AS), and by phone on Day 8 
(AS) and Day 20 (AS).
Sub-sample
All 72 participants in the parent study were contacted for 
telephone pill counts, however, 13 were lost to follow-up 
at Month 1, eleven completed one pill count (telephone or 
in-person) but not both, and two pocketed too many doses of 
their medications to be reliably counted, leaving a final sam-
ple of 46 participants (22 SC, 24 AS) with complete Month 1 
unannounced telephone and in-person pill count data. These 
46 comprise the sub-sample for the current study.
Participants and screening
Inclusion criteria included being African-  American, 18 years 
of age, smoking .10 cigarettes per day, being interested in 
quitting, willing to take varenicline, and having a functioning 
telephone number. Participants were excluded if they were 
planning to move from the area within 3 months or had con-
traindications to the use of varenicline, including: a cardiovas-
cular event in the month prior to enrollment; renal impairment; 
taking insulin for diabetes but unwilling to closely monitor 
blood sugar; history of clinically significant allergic reactions to 
varenicline; a major depressive disorder in the past year requir-
ing treatment; history of alcohol or drug dependency in the 
past year; history of psychosis, panic disorder, bipolar disorder 
or any eating disorders; or current breast-feeding, pregnancy or 
plans to get pregnant in the next 3 months.21 Participants were 
enrolled between March and August 2009. Written informed 
consent was obtained from all participants. All study procedures 
were approved and monitored by the University of Kansas 
Medical Center’s human subjects committee.
Medication dispensing
Participants received a 1-month supply of varenicline, or 
57 pills, dosed according to standard guidelines in a 30-day 
pill box at baseline. Participants were scheduled to return to 
the clinic at Month 1 for a medication refill.
Pill counts
Pill counts were completed by trained research staff follow-
ing a standardized protocol adapted from previous studies 
whereby the number of pills remaining in each compart-
ment of the pill box (ie, 0, 1, or 2 pills) was opened and 
recorded.18–20 Participants were told that they would receive 
periodic checks to assess their experience with the medica-
tion; however, they were unaware that a pill count would be 
completed at either the Month 1 refill visit or by phone a few 
days prior to this visit.
Unannounced telephone pill count
Unannounced telephone assessments occurred 3–4 days prior 
to the Month 1 visit. Research staff phoned participants, 
confirmed that it was a good time for them to talk, and asked 
them to retrieve their pill box. Following a standardized script, 
participants were told that the assessments were being done 
to better understand what people in the study were doing 
with their pills. They were told not to worry about telling 
the research staff if they missed or had stopped taking their 
medication because the purpose was to understand the good 
and bad aspects of taking the medication so that we could 
better help participants in the future. Research staff then 
asked participants to open each compartment of their pill 
box, one-by-one, and to report the number of pills remaining 
in each compartment.
in-person pill counts
In-person pill counts were completed by research staff at the 
Month 1, 2, and 3 medication refill visits. In-person counts 
followed the exact same protocol and script as the telephone 
counts, the only difference being that research staff, not the 
participant, opened and recorded the number of pills observed 
in each compartment.
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Outcome variables
Concordance of pills counted
The number of pills remaining in each compartment of the pill 
box (ie, untaken/missed doses) was recorded onto data sheets 
and summed to provide the total number of pills counted. 
Separate data sheets were completed for the unannounced 
and in-person pill count assessment to limit the potential for 
bias. For ease of interpretation, the days between completion 
of the unannounced pill count and the in-person assessment 
were excluded so that the sum of pills counted by telephone 
and in-person were for the exact same time frame.
Other variables of interest
Baseline demographic, psychosocial, and medication/
treatment-related variables were included to examine if 
participants with discordant phone and in-person pill counts 
differed from participants with perfectly concordant counts. 
Variables were selected based on factors known to be associ-
ated with poor adherence in the literature.13,22
Demographic characteristics
Demographic information included age, gender, education, 
marital status, monthly family income, cigarettes smoked per 
day, and type of cigarette smoked (menthol, non-menthol).23 
The three-item Alcohol Use Disorders Identification Test-
Consumption (AUDIT-C) was used to assess problem 
drinking, with scores of three or greater indicating possible 
problems with alcohol.24,25 Use of marijuana or other drugs 
was assessed using a single item, “During the past 7 days, 
have you smoked marijuana or used other drugs.”
Psychosocial characteristics
The ten-item Center for Epidemiological Studies Depres-
sion Scale (CES-D) was used to measure psychological 
distress, with scores of ten or higher indicating possible 
clinical   depression.26 A single item assessed motivation 
and confidence to quit smoking on a ten-point continuum 
ranging from ‘Not at all important/confident’ to ‘Extremely 
important/confident.’ This item has been used to assess moti-
vation and confidence to quit smoking in other studies.27–30 
A five-item motivation to adhere scale was used to assess 
participant’s motivation to take varenicline. This measure 
is grounded in motivational interviewing principles and has 
been found to be a reliable and valid measure of motivation to 
adhere to HIV medications.31,32 Confidence to take varenicline 
in the face of common challenges – eg, changing eating habits, 
making them feel sick – was assessed using an adapted version 
of the ten-item HIV treatment adherence self-efficacy scale.33 
The six-item God Locus of Health Control (GLHC) measure 
was used to assess participant’s perception of God’s control 
over whether they quit smoking.34
Medication/treatment-related characteristics
Adherence was computed from the Month 1 in-person pill 
count by dividing the number of pills taken (pills prescribed 
minus pills counted) by the number of pills prescribed 
times 100. For example, participants were prescribed 57 pills 
during month 1. If three pills were counted, adherence was cal-
culated as 57 - 3 [pills taken]/57 × 100. Participants were asked 
about ten symptoms associated with quitting smoking and/or 
  smoking cessation pharmacotherapy (eg, fatigue, trouble sleep-
ing, irritability), including the severity of each reported symp-
tom. A similar medication symptoms checklist has been 
used in published clinical trials to examine side effects of 
varenicline.21,35–43 Past medication taking behaviors were 
assessed using the Medication Adherence Questionnaire.44,45 
Treatment group assignment (Adherence Support vs Standard 
Care) was compared between participants with concordant 
and discrepant pill counts.
Statistical analyses
Continuous variables were described using mean and standard 
deviation. Similarly, categorical variables were described using 
frequency and percentage. We primarily performed analyses to 
assess the concordance between the unannounced telephone 
and in-person based pill counts. We tested agreement using 
Spearman’s correlation. Using the non-parametric Wilcoxon 
for continuous variables and the Fischer’s exact test for 
categorical variables, we compared participants who had 
perfectly concordant unannounced telephone and in-person 
pill counts with participants who had discrepant pill counts 
on demographic and psychosocial characteristics. Given the 
small sample size and the number of comparisons, Bonferroni 
corrections were applied to these comparisons such that only 
those variables significant at P , 0.003 were considered sta-
tistically significant. All analyses were performed using SAS 
(©2002–2008 by SAS Institute Inc, Cary, NC).
Results
Participants
No statistically significant differences were found on any of 
the demographic, psychosocial, or medication/treatment-
related factors between our sub-sample of 46 and the 
26 participants in the parent study with incomplete data who 
were excluded from the current analyses. Participants were 
all African-American, 27 women and 19 men, with a mean 
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age of 48.1 (SD = 12.6) years. The majority (82.6%) had a 
high school education or more but were predominately low 
income (59.5% had a family income of ,$1,800/month). 
Participants smoked menthol cigarettes (80.4%), averaged 
17.1 (SD = 6.7) cigarettes per day and were highly motivated 
to quit smoking (9.9 [SD = 0.5] out of a possible 10).
Concordance of pills counted
Unannounced telephone pill counts were completed an aver-
age of 4.2 (SD = 3.9) days before the in-person pill count. 
The correlation between the phone and in-person pill counts 
was rs = 0.94 (P , 0.0001), with an average of 3.6 (7.1) pills 
being counted by telephone and 3.9 (7.1) pills being counted 
in-  person. Contacting 46 participants for the unannounced 
telephone pill count required a total of 85 call attempts, with 20 
(43.4%) participants contacted on their first attempt, 13 (28.3%) 
contacted on their second attempt, and 13 (28.3%) requiring 
three or more phone attempts to reach them. A   summary of costs 
for the telephone and in-person pill counts is shown in Table 1. 
The average cost per telephone pill count was $2.18, while the 
average cost per in-person pill count was $7.24.
Analysis of discrepant counts
Of the 46 participants, 39 participants (85%) had Month 1 
unannounced phone and in-person pill counts that were exactly 
the same – ie, concordant – and seven (15%) had unan-
nounced phone and in person pill counts that were discordant. 
Analysis of the seven discordant counts showed that a mean 
of 4.0 (SD = 3.2) fewer pills were counted over the phone 
compared to in-person (ie, missed pills were underreported 
over the phone). Comparisons between participants with 
discordant pill counts (n = 7), and those who had precisely 
the same unannounced telephone and in-person pill counts 
(n = 39) are shown in Table 2A and B. Participants with dis-
crepant pill counts had lower medication adherence rates at 
Month 1 (77% [18%] vs 95% [9%], P , 0.0005); however, 
they reported better adherence to medications in the past (1.0 
[0.8] vs 2.8 [1.0], P , 0.0004) compared to participants with 
matching phone and in-person pill counts.
Discussion
This study obtained high levels of concordance for pills 
counted and medication adherence rates between unan-
nounced pill counts by telephone and those conducted in-per-
son. These findings are consistent with other health studies that 
have found concordance rates of 0.981–0.997 between unan-
nounced telephone and in-person pill counts.19,20   Consistent 
relationships have been found between   pharmacotherapy use 
and higher rates of smoking abstinence,3–6,46 yet little atten-
tion is given to monitoring pharmacotherapy use in smoking 
cessation clinical trials. Findings from this study suggest that 
unannounced telephone pill counts may be a viable and prac-
tical alternative for objectively measuring pharmacotherapy 
adherence in smoking cessation clinical trials.
Unannounced telephone pill counts may be more feasible 
to implement than in-person counts and have a number of 
advantages over other approaches.13,19 Unannounced tele-
phone pill counts minimize many challenges associated with 
office-based pill counts (eg, dumping pills in anticipation of 
a pill count, forgetting medication for the office visit) and 
reduce participant burden (eg, time and travel), which allows 
for more regular monitoring of medication taking. Nearly 
half of the participants in this study were contacted on their 
first attempt, with the majority being contacted on the first or 
second attempt. Telephone pill counts also cost less than in-
person counts. The cost per telephone pill count in this study 
was $2.18 compared to $7.24 for the in-person counts. These 
figures are similar to a study conducted by Kalichman et al 
which found that phone-based pill counts cost $7.65, on aver-
age, compared to $19.61 for in-person counts, and suggests 
that telephone pill counts are more cost effective to implement 
than in-person counts.20
Pill boxes were used in this study to simplify and improve 
the accuracy of the pill count protocol – ie, participants opened 
each pill box compartment and reported the number of pills 
remaining; they did not have to remove varenicline from pill 
bottles, sort, and count their medication using pharmacy trays, 
an approach that may be prone to lost pills and counting errors. 
Although other studies have shown that pill boxes may lead 
to increased error and misreporting,19,20 pill boxes appeared to 
be useful in this study. The mean rate of adherence to vareni-
cline was 92%. This is consistent with research showing that 
  adherence to medications is higher among participants who 
use a pill box compared to those who do not.47 We did not 
Table 1 Summary of costs for the telephone vs in-person pill 
counts
Cost variables Telephone 
pill count
In-person 
pill count
Salary with fringe benefits $13.05 per hour $13.05 per hour
Time spent reaching  
participants for pill count
2 minutes –
Time spent counting pills 8 minutes 8 minutes
Phone line $0.03 per hour –
Average participant  
mileage to clinic
– 10 miles
Mileage reimbursement – $0.55/mile
Total costs $2.18 per pill count $7.24 per pill count
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have a no-pill box comparison group in this study, and cannot 
conclude that the use of pill boxes led to increased adherence. 
However, pill boxes are a method of organization; participants 
can open a compartment to easily determine whether they have 
taken the medication on a given day compared to a pill bottle 
where the determination of whether medication has been taken 
is more difficult. Given the use of pill boxes as a common 
adherence aid and previous research that has found that pill 
boxes increase medication adherence by as much as 5% com-
pared to a no-pill box condition,47 we speculate that pill boxes 
used in conjunction with unannounced telephone monitoring 
could improve medication adherence and, in turn, increase 
rates of smoking abstinence. Pill boxes may also be preferred 
over other methods of medication monitoring. In a community-
based sample of predominately low-income African-American 
women with hypertension, one-third preferred a pill box over a 
Medication Event Monitoring System (MEMS), an electronic 
bottle cap that records the exact date and times that bottles are 
opened,48 suggesting that pill boxes may be a better tool for 
monitoring adherence in some populations.
The study has limitations. First, this is a pilot study with 
a small sample size comprised of mostly African-American 
women recruited from a single community health center; 
therefore results may not generalize to a more diverse sample. 
Second, due to the small sample size and the relatively low 
number of participants with discrepant counts, comparisons 
between participants with concordant and discrepant pill 
counts were limited in the power to detect statistically sig-
nificant differences and the differences found should be inter-
preted with caution. Finally, it is possible that   participants 
Table 2B Categorical demographic, psychosocial, and medication/treatment related characteristics of participants with discordant and 
concordant pill counts (N = 46)
Characteristic Discordant pill counts Concordant pill counts P
(N = 7) (N = 39)
Demographic
Female, n (%) 6 (85.7%) 21 (53.9%) ns
Married or living with partner, n (%) 3 (42.9%) 15 (38.5%) ns
Monthly family income ,$1,800, n (%) 5 (71.4%) 20 (57.1%) ns
,High school education, n (%) 2 (28.6%) 6 (15.4%) ns
Menthol cigarettes, n (%) 6 (85.7%) 31 (81.6%) ns
Use of marijuana or other drugs, n (%) 1 (14.3%) 4 (10.3%) ns
Psychosocial
Possible clinical depression, n (%) 2 (28.6%) 11 (28.2%) ns
Treatment-related
Treatment group, adherence support, n (%) 6 (85.7%) 18 (46.2%) ns
Table 2A Baseline continuous demographic, psychosocial, and medication/treatment related characteristics of participants with 
discordant and concordant pill counts (N = 46)a
Characteristic Discordant pill counts  Concordant pill counts  P
(N = 7) (N = 39)
Demographic
Age 48.7 (13.4) 47.9 (12.7) ns
Psychosocial
Alcohol use (AUDiT-C; 0–12),b mean, (SD) 1.9 (1.6) 2.8 (2.7) ns
Depression (CES-D-10; 0–30)c mean, (SD) 6.9 (6.7) 7.3 (5.4) ns
God’s control over quitting (GLHC; 0–36), mean, (SD) 26.7 (10.8) 18.7 (9.3) ns
Motivation to take medication (0–50), mean, (SD) 43.7 (10.4) 49.3 (1.3) ns
Confidence to take medication (0–100), mean, (SD) 92.3 (12.1) 91.1 (9.5) ns
Motivation to quit smoking (0–10), mean, (SD) 10.0 (0.0) 9.8 (0.1) ns
Confidence to quit smoking (0–10), mean, (SD) 9.0 (1.9) 8.5 (1.8) ns
Medication/treatment-related
Number of moderate to severe side effects, mean, (SD) 0.9 (0.9) 0.5 (0.9) ns
Prior medication adherence (MAQ; 0–4),e mean, (SD) 1.0 (0.8) 2.8 (1.0) 0.0004
Month 1% adherence (per in-person pill counts), mean, (SD) 77 (0.18) 95 (0.09) 0.0005
Notes:  aAll measures were taken at baseline, unless otherwise noted;  bAlcohol Use Disorders Identification Test-Consumption;  cCenter for Epidemiological Studies 
Depression Scale; dGod Locus of Health Control; eMedication Adherence Questionnaire (higher scores indicate non-compliance).
Abbreviations: SD, standard deviation; CES-D, Center for Epidemiological Studies Depression Scale; GLHC, God Locus of Health Control; MAQ, Medication Adherence 
Questionnaire.
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anticipated having their medications counted during the 
Month 1 refill visit and removed pills after the unannounced 
telephone pill count. We safeguarded against this possibility 
by blinding participants to both pill counts. In addition, we 
achieved concordance rates for pills counted that are similar 
to those achieved in studies where in-person counts were 
completed immediately following telephone counts.19,20
Further research is needed among a larger and more 
diverse sample to confirm and improve the generalizability 
of the findings. Research is also needed to compare the utility 
of unannounced telephone pill counts for smoking cessation 
pharmacotherapy with other objective methods of medication 
monitoring – eg, MEMS, immediate in-person unannounced 
pill counts. Studies in other health domains have found a high 
degree of concordance between unannounced telephone pill 
counts and electronic (MEMS) monitoring,16,18 but this should 
be confirmed with smoking cessation pharmacotherapy. 
Each method has its respective advantages and disadvan-
tages. Telephone pill counts may be preferred among some 
populations48 and may lend themselves best to non-nicotine 
therapies – ie, varenicline, bupropion. Methods for monitor-
ing use of NRTs – ie, nicotine gum, patch, nasal spray, inhaler, 
and lozenge – warrant further attention.
In conclusion, better strategies are needed to monitor 
medication adherence in smoking cessation clinical trials. 
Unannounced telephone pill counts may represent one such 
approach. Telephone pill counts are feasible and may reduce 
burden and costs compared to in-person counts.
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